Skip to main
LUNG

Pulmonx (LUNG) Stock Forecast & Price Target

Pulmonx (LUNG) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 0%
Hold 43%
Sell 0%
Strong Sell 0%

Bulls say

Pulmonx Corp demonstrated a solid financial performance in the third quarter of 2025, reporting revenue of $21.5 million, which represents a 5% year-over-year increase attributed to the growing adoption of its Zephyr Endobronchial Valve. The company upheld a strong gross margin of 75% and improved its gross profit to $16.1 million, indicating efficient cost management amid a narrowed net loss of $14.0 million. Furthermore, Pulmonx's strategic initiatives in international markets, evidenced by a 15% sales increase to $7.5 million, along with ongoing investment in innovation and disciplined execution, underscore a positive long-term growth outlook.

Bears say

Pulmonx Corp experienced a sequential revenue decline in Q3, with reported revenue of approximately $21.5 million compared to $23.9 million in Q2, indicating a slowdown in financial performance that prompted a guidance revision for the year. The company's management transition, with Glen French returning as CEO and Derrick Sung appointed as COO/CFO, adds an element of uncertainty to operational execution, further heightening execution risks related to product models. Additionally, the pressure on top-line growth, along with a dip in gross margins from 72% in Q2 due to mix and conversion timing, reinforces concerns about the company's financial stability moving forward.

Pulmonx (LUNG) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 0% recommend Buy, 43% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pulmonx (LUNG) Forecast

Analysts have given Pulmonx (LUNG) a Buy based on their latest research and market trends.

According to 7 analysts, Pulmonx (LUNG) has a Buy consensus rating as of Jan 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.81, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.81, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pulmonx (LUNG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.